Last reviewed · How we verify

Betaglucin soluble gel 0.2%

Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · Phase 3 active Small molecule

Betaglucin soluble gel 0.2% is a Immunomodulator Small molecule drug developed by Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri. It is currently in Phase 3 development for Cancer immunotherapy (adjunctive), Immune enhancement in infectious diseases.

Betaglucin is a beta-glucan immunomodulator that enhances innate immune responses by activating pattern recognition receptors on immune cells.

Betaglucin is a beta-glucan immunomodulator that enhances innate immune responses by activating pattern recognition receptors on immune cells. Used for Cancer immunotherapy (adjunctive), Immune enhancement in infectious diseases.

At a glance

Generic nameBetaglucin soluble gel 0.2%
SponsorCentro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri
Drug classImmunomodulator
TargetComplement receptor 3 (CR3), Dectin-1
ModalitySmall molecule
Therapeutic areaImmunology / Oncology
PhasePhase 3

Mechanism of action

Beta-glucans are polysaccharides derived from fungal cell walls that bind to complement receptor 3 (CR3) and dectin-1 on macrophages, neutrophils, and dendritic cells, triggering enhanced phagocytosis and cytokine production. This activation of innate immunity is proposed to improve immune surveillance and response to pathogens and potentially malignant cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Betaglucin soluble gel 0.2%

What is Betaglucin soluble gel 0.2%?

Betaglucin soluble gel 0.2% is a Immunomodulator drug developed by Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri, indicated for Cancer immunotherapy (adjunctive), Immune enhancement in infectious diseases.

How does Betaglucin soluble gel 0.2% work?

Betaglucin is a beta-glucan immunomodulator that enhances innate immune responses by activating pattern recognition receptors on immune cells.

What is Betaglucin soluble gel 0.2% used for?

Betaglucin soluble gel 0.2% is indicated for Cancer immunotherapy (adjunctive), Immune enhancement in infectious diseases.

Who makes Betaglucin soluble gel 0.2%?

Betaglucin soluble gel 0.2% is developed by Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri (see full Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri pipeline at /company/centro-de-investigaciones-medicas-y-ensayos-clinicos-dr-italo-fabbri).

What drug class is Betaglucin soluble gel 0.2% in?

Betaglucin soluble gel 0.2% belongs to the Immunomodulator class. See all Immunomodulator drugs at /class/immunomodulator.

What development phase is Betaglucin soluble gel 0.2% in?

Betaglucin soluble gel 0.2% is in Phase 3.

What are the side effects of Betaglucin soluble gel 0.2%?

Common side effects of Betaglucin soluble gel 0.2% include Injection site reactions, Fever, Fatigue.

What does Betaglucin soluble gel 0.2% target?

Betaglucin soluble gel 0.2% targets Complement receptor 3 (CR3), Dectin-1 and is a Immunomodulator.

Related